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Abstract
This study aimed to determine the pattern of [18F]flortaucipir uptake in individuals affected by Gerstmann-
Sträussler-Scheinker disease (GSS) associated with the PRNP F198S mutation. The aims were to: 1) determine the
pattern of [18F]flortaucipir uptake in two GSS patients; 2) compare tau distribution by [18F]flortaucipir PET imaging
among three groups: two GSS patients, two early onset Alzheimer’s disease patients (EOAD), two cognitively normal
older adults (CN); 3) validate the PET imaging by comparing the pattern of [18F]flortaucipir uptake, in vivo, with that
of tau neuropathology, post-mortem. Scans were processed to generate standardized uptake value ratio (SUVR)
images. Regional [18F]flortaucipir SUVR was extracted and compared between GSS patients, EOADs, and CNs.
Neuropathology and tau immunohistochemistry were carried out post-mortem on a GSS patient who died 9
months after the [18F]flortaucipir scan. The GSS patients were at different stages of disease progression. Patient A
was mildly to moderately affected, suffering from cognitive, psychiatric, and ataxia symptoms. Patient B was
moderately to severely affected, suffering from ataxia and parkinsonism accompanied by psychiatric and cognitive
symptoms. The [18F]flortaucipir scans showed uptake in frontal, cingulate, and insular cortices, as well as in the
striatum and thalamus. Uptake was greater in Patient B than in Patient A. Both GSS patients showed greater uptake
in the striatum and thalamus than the EOADs and greater uptake in all evaluated regions than the CNs. Thioflavin S
fluorescence and immunohistochemistry revealed that the anatomical distribution of tau pathology is consistent
with that of [18F]flortaucipir uptake. In GSS patients, the neuroanatomical localization of pathologic tau, as detected
by [18F]flortaucipir, suggests correlation with the psychiatric, motor, and cognitive symptoms. The topography of
uptake in PRNP F198S GSS is strikingly different from that seen in AD. Further studies of the sensitivity, specificity,
and anatomical patterns of tau PET in diseases with tau pathology are warranted.
Keywords: Positron emission tomography (PET), [18F]flortaucipir/AV-1451/T-807, Gerstmann-Sträussler-Scheinker
disease (GSS), Tau, Prion protein (PrP), PRNP F198S mutation
Introduction
Gerstmann-Sträussler-Scheinker disease (GSS) [9] is a
rare dominantly inherited prion protein (PrP) amyloid-
osis. GSS patients, from a large kindred, have been ex-
tensively studied in three generations [13]; they carry a
TTC to TCC DNA change at codon 198 of the prion
protein gene (PRNP) resulting in a phenylalanine to
serine substitution (F198S) in the prion protein [6, 7, 11,
12, 14, 16, 35]. Neuropathologic examinations in these
patients have shown that the extracellular PrP amyloid
coexists with a severe intraneuronal tau pathology, char-
acterized by deposits of hyperphosphorylated tau and
neurofibrillary tangles (NFT) in the cerebral gray matter,
but not in the cerebellum [10, 11, 14]. Clinically, PRNP
F198S mutation carriers present with cerebellar
ataxia and dysarthria, with later bradykinesia and
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rigidity. These neurologic symptoms may be preceded
by psychiatric manifestations including drug depend-
ence, depression, and/or psychosis [7]. As the disease
progresses, memory impairment and cognitive dysfunc-
tion become severe [35].
In the brain of individuals carrying the PRNP F198S
mutation, PrP amyloid deposits occur in the form of
multicentric plaques and diffuse deposits throughout the
cerebral cortex, subcortical nuclei, cerebellum, and
brainstem [10, 12]. Neuropathologically, the pattern of
distribution of PrP amyloid differs substantially from
that of the amyloid β (Aβ) peptide, which is the major
component of the plaques in the dominantly inherited
and sporadic forms of Alzheimer’s disease (AD). Limited
neuropathologic data from non-symptomatic PRNP
F198S carriers suggest that extracellular PrP amyloid de-
posits precede the development of tau pathology [11].
Deposition of tau occurs in the form of tau-immunore-
active intracytoplasmic deposits in neurons, NFT, and
neuropil threads [10, 12]. By transmission electron mi-
croscopy and Western blot analysis, the neurofibrillary
tangles in GSS associated with the PRNP F198S muta-
tion are similar to those seen in AD [33]. Tau deposition
occurs in close proximity to the PrP amyloid deposits, and
thus, the pattern of tau pathology in the cerebrum mirrors
that of PrP amyloid. As a consequence, both tau spread
and topography in this prion disease differ substantially
from those observed in AD and other neurodegenerative
diseases with tau pathology.
Neuroimaging studies of patients with GSS have
employed structural magnetic resonance imagin (MRI),
positron emission tomography (PET), and single photon
emission computerized tomography (SPECT). To date,
only a few studies have evaluated neuroimaging mea-
sures in PRNP F198S GSS patients. Vitali et al. (2011)
studied changes on fluid-attenuated inversion recovery
(FLAIR) and diffusion-weighted imaging (DWI) in pa-
tients with GSS, including two who carried the PRNP
F198S mutation and demonstrated hyperintense signal
in PRNP F198S individuals in limbic, neocortical, and
subcortical regions [36]. Kepe et al. (2010) evaluated al-
terations in GSS patients, including two symptomatic
and two asymptomatic PRNP F198S GSS patients from
the Indiana kindred, on 2-(1-(6-[(2-[fluorine-18]fluor-
oethyl)(methyl)amino]-2-naphthyl)-ethylidene)malononi-
trile ([18F]FDDNP) PET, [18F]fluorodeoxyglucose (FDG)
PET, and structural MRI [19] images. In that report, the
symptomatic PRNP F198S GSS patients and one asymp-
tomatic carrier had increased [18F]FDDNP binding in
the basal ganglia, thalamus, cerebral cortex, and cerebel-
lum. Reduced metabolism and mild atrophy were also
seen in similar regions in symptomatic PRNP F198S GSS
patients. Recently, another study demonstrated that
[11C]PiB, which is selective for Aβ deposition, showed
no specific signal in asymptomatic and symptomatic indi-
viduals carrying the PRNP P102L mutation or the PRNP
F198S mutation [4]. Currently, no ligand is available to
specifically demonstrate PrP amyloid deposition by PET.
In this study, we sought to: 1) determine the pattern of
[18F]flortaucipir uptake in PRNP F198S GSS patients; 2)
compare the tau distribution on [18F]flortaucipir PET
among the following three groups: PRNP F198S GSS af-
fected individuals, sporadic early onset AD patients
(EOAD), cognitively normal older adults (CN); and, 3)
compare the pattern of [18F]flortaucipir uptake, in vivo,
with that of tau neuropathology, post-mortem. Based on
the neuropathological similarity of the tau NFT in PRNP
F198S GSS and AD [33], we hypothesized that [18F]flor-
taucipir, a recently developed PET tracer that is specifically
sensitive to tau NFTs [2, 37], would permit in vivo detec-
tion of tau deposits in PRNP F198S GSS patients. In the
present study, we report, for the first time, data showing
[18F]flortaucipir uptake in two symptomatic GSS indivi-
duals carrying the F198S PRNP mutation and compare the
uptake patterns in these individuals with patterns observed
in cognitively normal older adults (CN) and in patients
with EOAD. The [18F]flortaucipir PET results are also
validated by the neuropathologic demonstration of PrP
amyloid and tau deposits in one of the two GSS patients,
who died 9 months after the [18F]flortaucipir PET scan.
Materials and methods
Clinical assessment
All participants were evaluated in the context of annual
research visits to the Indiana Alzheimer Disease Center
(IADC). The clinical assessments included neurological
examinations, structured informant interviews for symp-
toms and function, and neuropsychological assessments.
Diagnoses were made by consensus panel using research
criteria. Assessments were compliant with National Alz-
heimer’s Coordinating Center (NACC) procedures at the
time of the visits including: demographics, health histor-
ies, medications, family histories, Clinical Dementia Rat-
ing (CDR), Functional Assessment Scale (FAS), Geriatric
Depression Scale (GDS), and Neuropsychiatric Interview
Questionnaire (NPI-Q). At the time of the [18F]flortauci-
pir PET scans, cognitive testing with the UDS3 measures
included: Montreal Cognitive Assessment (MoCA), Craft
Stories immediate and delayed recall, Benson Complex
Figure copy and delayed recall, the Multilingual Naming
Test (MINT), Animal fluency, Vegetable fluency, Phon-
emic fluency (letters F and L), Trail Making Test Parts A
and B (TMT-A and TMT-B), and Number Span forward
and backward. The Rey Auditory Verbal Learning Test
(RAVLT) and Digit Symbol Substitution Test were also
given to all participants. Written informed consent was
obtained from all participants in accordance with the
Declaration of Helsinki and the Belmont Report. All
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procedures were approved by the Indiana University
School of Medicine Institutional Review Board.
Genetics
DNA was extracted from fresh blood samples of patients
A and B and the open-reading frame of the Prion Pro-
tein gene (PRNP) was analyzed by direct sequencing.
The same procedure was used to study DNA extracted
from the brain tissue of patient B and several previously
deceased family members [16].
Structural MRI
A T1-weighted magnetization-prepared rapid gradient-
echo (MPRAGE) structural MRI sequence was acquired
at the time of the [18F]flortaucipir PET scan on a 3 Tesla
Siemens Prisma scanner for both patients. Automatic
parcellation with Freesurfer version 5.1 (https://surfer.
nmr.mgh.harvard.edu/fswiki/FreeSurferWiki) was comple-
ted to create subject-specific regions of interest (ROIs) to
use for extraction of mean [18F]flortaucipir standardized
uptake value ratio (SUVR; see [18F]Flortaucipir section)
from target regions. MPRAGE scans were also segmented
in Statistical Parametric Mapping 8 (SPM8) to generate
subject-specific spatial normalization parameters for use
in PET scan processing.
[18F]Flortaucipir PET
Both patients were studied with [18F]flortaucipir PET
within two months of the nearest clinical visit (mean age
in the sixth decade). They were injected intravenously
with approximately 10 mCi of [18F]flortaucipir and after a
75-min uptake period were scanned for 30 min on a Sie-
mens mCT (six 5-min frames). Scans were reconstructed
according to the Alzheimer’s Disease Neuroimaging Initia-
tive (ADNI)-2 protocol (http://adni.loni.usc.edu/wp-content/
uploads/2015/02/01_DOD-ADNI_Tau-Addendum-Protocol
_23Oct2014.pdf). Standard processing, including spatial
alignment for motion and normalization to Montreal
Neurologic Institute (MNI) space using parameters from the
MRI segmentation, was completed in SPM8. Mean static
images from 80 to 100 min post-injection were generated by
averaging the appropriate frames and smoothed with an
8 mm full-width half maximum (FWHM) Gaussian kernel.
Finally, [18F]flortaucipir SUVR images were generated by
intensity normalizing by mean cerebellar crus uptake. The
[18F]flortaucipir PET scans were qualitatively visualized
using MRIcron (http://www.mccauslandcenter.sc.edu/
mricro/mricron/). Mean [18F]flortaucipir SUVR values
were extracted from subject-specific ROIs, including the
caudate nucleus, putamen, pallidum, thalamus, insula, an-
terior cingulate gyrus, posterior cingulate gyrus, overall
lobar regions (frontal, parietal, temporal, and occipital),
the overall cingulate cortex, the sensory-motor cortices,
and the global cortex.
[18F]Flortaucipir PET scans from two CN (mean age of
approximately 67.5 years) and two Aβ-positive EOAD
patients (mean age of approximately 61 years; mean age
of onset of approximately 59 years) were used as com-
parisons. The patients were selected to match the PRNP
F198S GSS patients by sex and, as closely as possible, by
age and global cognition on the MoCA. All scans were
processed as described above. Scans were visualized
using MRIcron and mean SUVR was extracted from
Freesurfer-generated subject-specific ROIs for the re-
gions described above. For display purposes (Fig. 4),
mean SUVR values were calculated for the target ROIs
in both CN individuals and both EOAD patients as com-
parisons to the PRNP F198S GSS patients.
Neuropathology
Patient B expired 9 months after the [18F]flortaucipir PET
scan. The brain, harvested at Indiana University School of
Medicine, was hemisected along the mid-sagittal plane.
The left hemibrain was fixed in formalin. Following fix-
ation in a 10% formalin solution, the left cerebral and
cerebellar hemispheres, as well as the left half of the brain-
stem, were sliced and tissue samples were selected. In
order to compare neuropathology with tau PET imaging,
six hemispheric coronal slabs were selected that included
areas of the frontal, insular, temporal, parietal, and occipi-
tal lobes. These were submitted in their entirety for hist-
ology and immunohistochemistry. In addition, blocks of
the following CNS areas were also submitted: superior
frontal gyrus, middle frontal gyrus, anterior cingulate
gyrus, superior temporal gyrus, middle temporal gyrus,
hippocampus at two levels, entorhinal cortex, precentral
cortex, postcentral cortex, inferior parietal lobule, poster-
ior cingulate gyrus and precuneus, calcarine cortex,
caudate nucleus, putamen, globus pallidus, amygdala,
claustrum, thalamus, subthalamic nucleus, cerebellar ver-
mis, cerebellar cortex and dentate nucleus, midbrain,
pons, medulla, and spinal cord at cervical, thoracic, lum-
bar, and sacral levels. The areas submited were representa-
tive of the following Brodmann Areas: 1, 2, 3, 4, 5, 6, 7, 8,
9, 11, 12, 17, 18, 19, 20, 21, 22, 23, 24, 27, 28, 31, 32, 36,
37, 38, 44, 47. The right hemibrain was sliced, frozen, and
stored at − 70 °C for structural, biochemical and molecular
genetic studies of PrP and tau and for the analysis of the
seeding properties of PrP and tau in PRNP F198S GSS.
Brain tissue samples from the left hemibrain were
dehydrated in graded alcohols, cleared in xylene, and
embedded in paraffin. Eight-micrometer-thick sections
from multiple brain areas were stained using the histo-
logical and immunohistochemical methods described
below. Hematoxylin and eosin (H&E) and Luxol fast
blue-hematoxylin & eosin (LFB-H&E) were used to sur-
vey gray and white matters for neuronal loss, gliosis, vas-
cular pathology, and other possible pathologic lesions.
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The Thioflavin S method was used to visualize amyloid
deposits and neurofibrillary tangles. Prussian blue stain
enhanced by DAB (Prussian Blue-DAB) visualized the fer-
ric iron deposits in the tissue. Neurodegenerative path-
ology was further analyzed using antibodies raised against
PrP (3F4, 1:800, Dr. Richard Kacsak, Staten-Island, New
York, USA), tau (AT8, 1:300, Thermo Fisher Scientific,
Waltham, MA, USA; PHF-1, 1:10, gift of Dr. P. Davies);
3-repeat tau (3R, 1:3000, Millipore, Billerica Massachu-
setts, USA), 4-repeat tau (4R, 1:100, Millipore, Billerica
Massachusetts, USA), anti-phospho-TDP-43 (1:1000,
Cosmo Biologicals, Carlsbad, CA, USA), α-synuclein
(ASy119–137, 1:300, Dr. P. Piccardo, Dr. B. Ghetti) and
amyloid β (Aβ 21F12, 1:1000, Janssen Research & Deve-
lopment, South San Francisco, CA, USA). AT8 recognizes
tau phosphorylated at serine 202 and threonine 205, while
PHF-1 recognizes tau phosphorylated at serine 396 and
serine 404. The signal from polyclonal or monoclonal
antibodies was visualized using avidin-biotin, with goat
anti-rabbit immunoglobulin or goat anti-mouse as the
secondary antibody as required, followed by horseradish
peroxidase-conjugated streptavidin and the chromogen di-
aminobenzidine. Immunohistochemical sections were
counterstained with hematoxylin.
Results
Case histories
Patient A
Patient A had a family history of GSS and completed
15 IADC clinical yearly assessments before the tau PET
scan. The subject was right-handed, had a few years of
college education, and was first examined neurologically
in their fourth decade. At the first twelve annual visits,
clinical, neurologic, and neuropsychological assessments
were within normal limits in all respects. During this
time period, Patient A was found to have the PRNP
F198S mutation. In the sixth decade, Patient A devel-
oped mild depression and the patient’s informant re-
ported the onset of a gradually progressive memory
impairment accompanied by a change in personality,
characterized by sadness and withdrawal developing over
an 18-month period. The NPI-Q also indicated mild ap-
athy and irritability. Otherwise, the neurological and
neuropsychological exams were unremarkable and the
patient was determined to be cognitively normal. Ap-
proximately 1 year later, the patient’s informant reported
mild worsening of the psychiatric symptoms, including
mild depression, irritability, and changes in motor be-
haviors. Neurologically and cognitively, however, the pa-
tient was considered normal except for a mild decline in
psychomotor speed that remained within the normal
range for the patient’s age. The neurological examination
on the next visit, approximately 1 year later,was again
unremarkable but the supplemental CDR for the
behavioral, comportment, and personality domains now
indicated mild impairment (a 0.5 rating). NPI-Q revealed
progression of symptoms, including mild changes in
motor behaviors and mild ataxia, moderate depressive
and anxiety symptoms, and altered nighttime behaviors
and appetite. The neuropsychological battery indicated
mild decline in psychomotor speed and complex sequen-
cing, but these were still within the normal range. Nor-
mal cognition was again the consensus diagnosis.
The [18F]flortaucipir PET and the structural MRI scans
were completed at the sixteenth clinical assessment. The
informant reported a continued decline in memory, pro-
gressive changes in personality, as well as slowly progres-
sive decline in language. At the neurological examination,
gait abnormalities, slowness, and falls were observed.
Results of the neuropsychological examination are shown
in Table 1. The global CDR was 0.5, indicating mild global
impairment, with mild impairment (a 0.5 rating) in the
memory domain and mild-to-moderate impairment (a 1.0
rating) in the judgement and problem-solving domain. The
FAS indicated difficulty understanding books and TV
shows, difficulty remembering appointments and medica-
tions, and need for assistance with finances. The NPI-Q
again showed mild depressive symptoms, changes in motor
behavior, and changes in appetite. The neuropsychological
assessment revealed a decline in global cognitive status,
moderate impairment in complex sequential tracking and
psychomotor speed, moderate impairment in manual
motor skills, and mild impairment in new learning and
memory. Self-reported mood was within normal limits on
the GDS. The consensus diagnosis at this visit was mild
cognitive impairment due to GSS. One year following the
tau PET scan (the 17th clinical assessment), Patient A
showed progression of neurologic, psychiatric, and cogni-
tive symptoms; the informant reported continued gradually
progressive decline in memory, language, judgment, rea-
soning, and attention. The consensus diagnosis at that time
was mild dementia due to GSS.
Patient B
Patient B had a family history of GSS, was first assessed at
the IADC in the sixth decade, and was found to have the
PRNP F198S mutation. At time of the examination, the in-
formant reported a one-year history of gradually progres-
sive memory difficulties and a language disorder, as well
as a six-month history of difficulties with judgment and
reasoning, accompanied by changes in personality charac-
terized by irritability, withdrawal, sadness, socially in-
appropriate behavior, and agitation. On neurological
examination, there was slight tremor, bradykinesia, and
ataxic gait. The global CDR was 0.5, indicating mild global
impairment, with mild impairment (a 0.5 rating) in the
memory, orientation, judgement and problem-solving,
community affairs, and home and hobbies domains, and
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moderate impairment (a 1.0 rating) in the behavior, com-
portment, and personality domains of the supplemental
CDR. The NPI-Q indicated the presence of agitation, de-
pression, anxiety, disinhibition, irritability, nighttime be-
haviors, and problems with appetite, with severity scores
predominantly in the mild range. The FAS indicated mild
impairment in daily functioning, including shopping, play-
ing games, using and turning off the stove, meal prepar-
ation, keeping track of current events, remembering dates,
and traveling out of the neighborhood. The neuropsycho-
logical battery revealed mild impairments in efficiency of
new learning, verbal fluency, response inhibition, complex
sequential tracking, and manual motor speed. The
Mini-Mental State Examination score was 26/30. The
GDS was within normal limits. The consensus diagnosis
was mild dementia due to GSS.
At the follow-up IADC assessment approximately 1
year later, the informant reported continued loss of
memory, language, judgment, and reasoning, as well as
continued deterioration in personality, including the
appearance of delusions. On neurological examination,
there was evidence of parkinsonism and slowness, with
frequent falls and gait disturbance. Results of the neuro-
psychological examination are shown in Table 1. The
global CDR had worsened to 1.0, indicating mild impair-
ment, with very mild impairment (a 0.5 rating) in mem-
ory and orientation domains, mild to moderate
impairment (a 1.0 rating) in judgement and
problem-solving, community affairs, and personal care
domains, and severe impairment (a 3.0 rating) in the
home and hobbies domain. The NPI-Q now included
delusions in addition to the problems noted on the pre-
vious visit, with most symptoms rated as moderate in se-
verity. The FAS total score had worsened to 13, with
need for assistance in shopping, simple meal preparation
and cooking, and traveling. The second neuropsycho-
logical examination revealed mild to moderate declines
in new learning, memory, executive cognitive function,
psychomotor speed, and manual motor skills. The
MoCA score was 18/30 (equivalent to a MMSE score of
Table 1 Neuropsychological performance of participants at the time of the [18F]flortaucipir scan
GSS Participants Early-Onset Alzheimer’s Cognitive Normals
Patient A Patient B Patient #1 Patient #2 #1 #2
MoCA 22 18 18 17 29 26
CDR Global 0.5 1 0.5 0.5 0 0
CDR Sum of Boxes 1.5 7 3 3.5 0 0
Digit Span Forward 10 5 10 8 9 9
Digit Span Backward 8 5 10 6 12 10
Trail Making Test A 49 76 53 35 23 20
Trail Making Test B 129 300 209 159 61 38
WAIS Digit Symbol 36 20 40 27 68 82
Animal Fluency 15 8 13 21 24 23
Vegetable Fluency 9 11 11 3 18 13
Letter Fluency 25 11 36 26 36 25
MINT 31 28 27 30 32 24
RAVLT Immediate 41 22 27 22 56 51
RAVLT Delayed 7 3 0 0 11 8
Craft Stories Immediate 9 5 6 5 18 15
Craft Stories Delayed 10 4 2 0 17 16
Benson Figure Copy 16 10 14 17 15 15
Benson Figure Recall 10 8 2 0 12 13
GDS 4 4 2 2 1 0
FAS 7 13 14 17 1 0
NPI-Q 3 10 7 9 1 2
Finger Tapping – Dom 39 24 48 58 39 42
Finger Tapping – ND 33 25 36 52 43 40
CDR Clinical Dementia Rating scale, Dom dominant hand, FAS Functional Assessment Scale, GDS Geriatric Depression Scale, GSS Gerstmann-Sträussler-Scheinker
disease, MINT Multi-lingual Naming Test, MoCA Montreal Cognitive Assessment, ND non-dominant hand, NPI-QNeuropsychiatric Inventory Questionnaire, RAVLT
Rey Auditory Verbal Learning Test, WAIS Wechsler Adult Intelligence Scale
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24/30 [34]) and GDS was within normal limits. The con-
sensus diagnosis was dementia due to GSS. The
[18F]flortaucipir PET and the structural MRI scans were
completed at this visit.
Patient B died while at hospice care 9 months after the
completion of the [18F]flortaucipir PET scan from pro-
gression of the GSS dementia.
Early-onset AD patient #1
EOAD patient #1 was found to be amyloid positive on a
[18F]florbetapir PET scan and showed medial temporal
and global atrophy on the structural MRI. At the time of
the [18F]flortaucipir PET scan, EOAD patient #1 was aged
in the seventh decade and had a global CDR of 0.5, indi-
cating mild impairment, with mild impairment (a 0.5 rat-
ing) in the orientation and judgment and problem-solving
domains and mild to moderate impairment (a 1.0 rating)
in the memory and home and hobbies domains, but nor-
mal functioning (a 0.0 rating) in the behavioral, comport-
ment, and personality domains of the supplemental CDR.
The informant reported a four-year history of gradually
progressive memory problems, a 1 year history of grad-
ually progressive problems with judgment and reasoning,
and a 3–4 month history of gradually progressive prob-
lems with attention and concentration. There were no
neurological abnormalities. Results of the neuropsycho-
logical examination are shown in Table 1. The NPI-Q re-
vealed depression and anxiety at a moderate level and
agitation, irritability, and abnormal nighttime behaviors at
a mild level of severity. The FAS total score was 14, indi-
cating mild difficulties with finances, shopping, meal prep-
aration, remembering appointments, pastimes, current
events, and travel outside of the neighborhood. The
neuropsychological battery revealed moderate impair-
ments in global cognitive status, complex sequential track-
ing, and psychomotor speed, and severe impairment in
new learning and memory. The consensus diagnosis was
dementia due to AD [25].
Early-onset AD patient #2
EOAD patient #2 was found to be amyloid positive on a
[18F]florbetapir PET scan and showed medial temporal
and global atrophy on the structural MRI. At the time of
the [18F]flortaucipir PET scan, EOAD patient #2 was aged
in the sixth decade and had a global CDR of 0.5, indicating
mild impairment, with mild impairment (a 0.5 rating) in
the judgment and problem-solving domain and mild to
moderate impairment (a 1.0 rating) in the memory, orien-
tation, and home and hobbies domains, and mild impair-
ment (a 0.5 rating) the behavioral, comportment, and
personality domains of the supplemental CDR. The in-
formant reported a three-year history of gradually pro-
gressive memory loss and a two-year history of gradually
progressive difficulty with judgment, reasoning, and
attention. There were no abnormal neurological manifes-
tations. Results of the neuropsychological examination are
shown in Table 1. The NPI-Q reflected mild problems
with delusions, depression, indifference, disinhibition, ir-
ritability, abnormal nighttime behaviors, and problems
with eating. The FAS total score was 17, indicating a sub-
stantial impairment and dependency in many activities of
daily living. The neuropsychological battery revealed mod-
erate impairment in global cognitive status and severe im-
pairment in new learning and memory. There were
moderate impairments in complex sequential tracking.
The consensus diagnosis was mild dementia due to AD.
Cognitively Normal individuals
At the time of their [18F]flortaucipir PET scans, both CN
individuals had global CDRs and Sum of Boxes scores of
0.0, with no informant-rated impairments or depression.
On examination, there were no neurological or neuro-
psychological abnormalities and consensus diagnoses were
normal cognition. Results of the neuropsychological
examination are shown in Table 1.
Genetics
There was a single nucleotide (T to C) substitution in
codon 198 of one allele of Patient A’s and Patient B’s
PRNP genes. This change results in a serine for phenyl-
alanine amino acid change (F198S). For patient A, the
first base of PRNP codon 129 was heterozygous guanine/
adenine (G/A), coding for valine/methionine (GTG/
ATG). For patient B, the first base of PRNP codon 129
was homozygous guanine (G), coding for valine (GTG).
[18F]Flortaucipir PET scans in PRNP F198S GSS patients
The [11C]PiB PET scans showed no specific uptake in
the Patients A and B, as previously reported ([4]; Add-
itional file 1: Figure S1). In contrast, the [18F]flortaucipir
PET scans showed significant uptake in multiple regions
in both GSS patients (Figs. 1, 2, and 4). As compared
with Patient A (Fig. 1), Patient B (Fig. 2) showed a more
severe clinical presentation and a wider spread of
[18F]flortaucipir uptake. GSS Patient A also showed evi-
dence of tracer uptake in regions (Fig. 1) that were not
seen in Patient B, including the primary sensory cortex
and the left temporal cortex. This [18F]flortaucipir up-
take was determined to be within cortical tissue and did
not correspond to any lesion observable on MRI. On vis-
ual inspection, both individuals showed uptake in the
basal ganglia, cingulate gyrus, insular cortex, and
thalamus.
Comparison of [18F]Flortaucipir between GSS patients,
Alzheimer’s patients, and cognitively normal individuals
Selected [18F]flortaucipir sections of the two GSS pa-
tients, two EOAD patients, and two CN older adults are
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shown in Fig. 3. Qualitatively, dramatically higher
[18F]flortaucipir uptake was observed in the basal ganglia
of Patient A (Fig. 3a) and Patient B (Fig. 3b) relatively to
the EOAD (Fig. 3c, d) and CN (Fig. 3e, f ) individuals. Less
dramatic, but still notable, increased uptake in the thal-
amus was observed in both GSS patients relative to the
EOAD and CN individuals. Further, greater uptake in the
cingulate gyrus, bilaterally, and in the insula, anteriorly,
was observed in GSS Patient B relatively to both CN indi-
viduals. Alternatively, the EOAD patients showed much
higher temporal, parietal, and frontal lobes [18F]flortauci-
pir uptake than the GSS patients and the CN individuals.
Fig. 1 [18F]Flortaucipir PET in Patient A – Mildly to Moderately Impaired PRNP F198S GSS Patient. [18F]Flortaucipir scans from a mildly to
moderately impaired GSS PRNP F198S mutation carrier (Patient a) show specific binding of the tracer in the basal ganglia, thalamus, insular cortex,
postcentral gyrus, and inferior temporal lobe. At a lower threshold (lower panels), additional binding is seen in the medial temporal lobe and
cingulate gyrus.
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Quantitative analysis confirmed much of the qualita-
tive observation of increased [18F]flortaucipir uptake in
GSS patients. Both GSS patients showed increased mean
[18F]flortaucipir SUVR in subcortical areas, including the
striatum and thalamus (Fig. 4a & b; Additional file 2:
Table S1). These areas were increased relative to both
the EOAD and CN individuals. Cortical areas such as in-
sula, anterior cingulate, posterior cingulate, and, globally,
in the cortical grey matter (Fig. 4c-f; Additional file 2:
Table S1) also showed increased mean [18F]flortaucipir
SUVR in the GSS patients relative to the CN individuals.
However, the EOAD patients showed considerably
greater mean [18F]flortaucipir SUVR in the majority of
cortical regions than either the CN individuals or GSS
patients.
Neuropathology
The fresh brain of Patient B weighed 1452.5 g. There
was no appreciable atrophy of the cerebral hemispheres
and no focal lesions or atheromatous changes were
noted on external examination. The left cerebral hemi-
sphere was cut into twenty-seven coronal slices. The
cerebellar cortex and the dentate nucleus appeared atro-
phic.The substantia nigra and the locus coeruleus were
moderately to severely depigmented. The inferior olivary
nuclei were atrophic.
Fig. 2 [18F]Flortaucipir PET in Patient B – Moderately to Severely Impaired PRNP F198S GSS Patient. [18F]Flortaucipir scans from a moderately to
severely impaired GSS PRNP F198S mutation carrier (Patient b) show specific binding of the tracer in the basal ganglia, thalamus, cingulate gyrus,
frontal lobe, and insula/claustrum
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Serial coronal sections, stained with LFB-H&E, re-
vealed mild and global cerebral atrophy, neuronal loss
and gliosis in the gray matter, as well as a diffuse loss of
myelin stain in the deep white matter of the frontal,
temporal, and parietal lobes (Fig. 5, 1st column).
In Thioflavin S-stained sections of cerebrum and cere-
bellum, diffuse plaques and plaques with multicentric
cores were numerous (Fig. 6a). The diffuse deposits were
not fluorescent, but appeared brighter than the sur-
rounding neuropil; the cores of the plaque were fluores-
cent and, therefore, have the tinctorial properties of
amyloid. In the Thioflavin S preparations of the cere-
brum, but not in preparations of the cerebellum, NFTs
were seen within neuronal perikarya and in neurites that
surround the amyloid cores.
Serial sections, adjacent to those stained with Thiofla-
vin S, were immunostained for PrP and revealed that
both diffuse plaques and plaques with amyloid core were
decorated by PrP antibodies (Fig. 6b). By PrP immuno-
histochemistry, labeling of the gray matter structures of
the cerebral hemisphere and of the cerebellum was ob-
served. PrP immunopositive diffuse and multicentric
cored plaques were extensively distributed in the neuro-
pil. No intracellular PrP inclusions were present. Within
the gray matter of the cerebral hemisphere, the most se-
vere PrP immunolabeling was seen in the superior, mid-
dle, and inferior frontal gyri, the cingulate gyrus, the
pre- and post-central gyri, the superior, middle and
inferior temporal gyri, the fusiform gyrus, the entorhinal
cortex, the parahippocampal gyrus, as well as the upper
portion of the insular cortex, the caudate nucleus, puta-
men, and thalamus (Fig. 5, 3rd column; Additional file 1:
Figure S1).
Serial sections, adjacent to those stained with Thioflavin
S and to those immunolabeled for PrP were immuno-
stained for tau. Decorated by the monoclonal antibodies
AT8 and PHF-1 were not just the NFTs, but also multiple
structures, including cytoplasm of neuronal perikarya,
dentritic processes, neuropil threads, and neurites sur-
rounding cores of plaques (Fig. 6c & d). In fact, using AT8
and PHF-1, the pattern of hyperphosphorylated tau im-
munohistochemical labeling mirrored that of PrP
throughout the cerebral cortex and the subcortical nuclei
except in the thalamus, where PrP immunoreactivity was
much stronger than tau immunoreactivity (Fig. 5, 4th col-
umn; Fig. 7; Additional file 1: Figure S1). Tau deposits
were most numerous in the superior, middle and inferior
frontal gyri, inferior temporal, fusiform, and cingulate gyri,
as well as in the insular, parahippocampal, and entorhinal
cortices, caudate nucleus, and putamen (Fig. 5, 4th col-
umn; Fig. 7). Patient B showed a large number of NFT
(Fig. 6d, Fig. 7). Tau deposits were not present in the cere-
bellar cortex.
In comparing tau immunolabeled tissue preparations
with those stained with Thioflavin S, it was evident that
profiles labeled with AT8 or PHF-1 were more numerous
Fig. 3 Qualitative Comparison of [18F]Flortaucipir PET in PRNP F198S GSS Patients Relative to Early-Onset Alzheimer’s Patients and Cognitively
Normal Older Adults. Comparisons of selected [18F]flortaucipir sections of the two GSS patients with two early-onset Alzheimer’s disease (EOAD)
patients and two cognitively normal older adults (CN) are shown. Higher [18F]flortaucipir uptake is observed in the basal ganglia of the PRNP
F198S GSS patients (a, b) relative to the EOAD patients (c, d) and CN individuals (e, f). In the PRNP F198S GSS patients, there is also increased
uptake in the thalamus relative to the EOAD patients and CN individuals. Greater uptake in the cingulate gyrus bilaterally is observed in PRNP
F198S GSS Patient B (b) relative to EOAD Patient #2 (d) and both CN individuals (e, f). There is slightly increased uptake in the anterior insula
bilaterally for PRNP F198S GSS Patient B (b) relative to EOAD Patient #2 (d) and both CN individuals (e,f)
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than the fluorescent profiles seen in Thioflavin S prepara-
tions (Fig. 6). However, it was also evident that AT8 ap-
peared to label a larger number of profiles than PHF-1
(Fig. 6; Fig. 7). These findings suggest that while Thioflavin
S detects exclusively the filament cores of tau NFTs, AT8
and PHF-1 label the NFTs, as well as portions of the tau
fuzzy coat, hyperphosporylated tau, and possibly tau in
various states of aggregation.
In AD, tau inclusions are immunopositive for 3R and 4R
tau [8]. Similarly, the tau aggregates in the GSS patient
were immunolabeled by monoclonal antibodies to 3R and
to 4R tau; however, the 4R antibody appeared to give a
stronger labeling than the 3R (Fig. 8).
Immunohistochemistry for Aβ revealed neither diffuse
nor cored plaques. Immunohistochemical preparations
using antibodies to TDP-43 and α-synuclein did not
show intracellular inclusions in neurons or glia.
Similar to what was observed previously in GSS F198S
affected individuals [11], ferric iron deposits in the brain
of Patient B were most abundant in the globus pallidus
and the substantia nigra (Fig. 9a-b), however at the
microscopic examination they were detected also in the
caudate nucleus and putamen. Iron deposits were not
detected in the thalamus (Fig. 9b).
Discussion
The PET tracer [18F]flortaucipir was used to investigate
the pattern of tau deposition in two GSS patients who
carry the PRNP F198S mutation and are members of a
pedigree that has been previously studied extensively
from the clinical and neuropathological points of view
[7, 11, 14, 35].
GSS caused by the PRNP F198S mutation is a PrP
amyloidosis associated with severe tau deposition in all
regions of the cerebrum and brainstem in which mis-
folded PrP amyloid is observed. On the contrary, tau
does not aggregate in the cerebellum, in spite of the
heavy PrP burden. DNA changes in the PRNP gene, in-
cluding missense, nonsense, insertion, and deletion mu-
tations, may be associated with a PrP amyloidosis that
coexists with severe tau deposition [1, 10, 14, 17, 20, 26,
31]. Patients with different forms of dominantly inher-
ited PrP amyloidosis may present with neuropsychiatric
manifestations including depression, personality
changes, psychosis, and hallucinations, as well as with
frontotemporal dementia-like phenotypes, similar to
those previously observed in some PRNP F198S muta-
tion carriers [7, 21, 30]. Therefore, it is notable that the
two GSS PRNP F198S carriers reported in the present
Fig. 4 Regional Quantitative Comparisons of [18F]Flortaucipir SUVR in PRNP F198S GSS Patients Relative to Early-Onset Alzheimer’s Patients and
Cognitively Normal Older Adults. Both PRNP F198S GSS patients showed increased mean [18F]flortaucipir SUVR in subcortical areas, including the
striatum (a) and thalamus (b) relative to early-onset Alzheimer’s disease (EOAD) patients and cognitively normal (CN) individuals. Cortical areas
such as the insula (c), anterior cingulate gyrus (d), posterior cingulate gyrus (e), and cortex global value (h) also showed increased mean
[18F]flortaucipir SUVR in the PRNP F198S GSS participants relative to the CN individuals, but not the EOAD patients
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study had neurological signs that were preceded by psy-
chiatric symptoms.
This study reveals for the first time that there is a con-
siderable uptake of [18F]flortaucipir in various brain re-
gions of both GSS patients with the PRNP F198S
mutation. Specifically, [18F]flortaucipir uptake is evident
in the anterior and posterior cingulate gyri, insular
cortex, caudate nucleus, nucleus accumbens, putamen,
globus pallidus, thalamus, and entorhinal cortex. Fur-
thermore, in comparing the more affected individual
with the less affected one, the uptake in the former was
greater than that in the latter in the majority of the re-
gions mentioned above. This suggests that a correlation
between clinical severity and [18F]flortaucipir uptake
Fig. 5 Neuropathologic Analysis of the Moderately to Severely Impaired GSS Patient B. Good correspondence between the [18F]flortaucipir SUVR
(5th column) and AT8 immunolabeling of tau (4th column) was observed across multiple regions, including the basal ganglia and cingulate gyrus
(a-c), as well as the frontal (a-d) and insular cortices (b,c,d). These areas also feature considerable structural atrophy on MRI (1st column) and LFB-
H&E stain (2nd column), as well as PrP amyloid deposition on 3F4 (3rd column). The only region of non-correspondence occurred in the
thalamus (d), where [18F]flortaucipir PET (5th column) showed increased uptake but no AT8 immunolabeling of tau (4th column) was observed;
PrP deposition was observed in the thalamus (3rd column). LFB-H&E = luxol fast blue with hematoxylin & eosin; MRI = magnetic resonance
imaging; PrP = prion protein
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may exist and that greater [18F]flortaucipir uptake may
correlate with a higher burden of aggregated tau.
Similar to what occurs in AD, the NFT present in
symptomatic PRNP F198S mutation carriers are made of
3R and 4R tau; however, the anatomical pattern of
[18F]flortaucipir PET uptake differs considerably from
that seen in early- and late-onset AD [5, 18, 28, 29, 32].
In AD, tau pathology as visualized by [18F]flortaucipir
PET, appears to be distributed over widespread brain
areas in the amnestic, non-amnestic, behavioral, cortico-
basal, and posterior cortical atrophy variants of the dis-
ease [29]. Further, tau PET patterns have been shown to
reflect the variability of clinical syndromes and topog-
raphy of pathologic regions [29]. Many of the anatomical
regions found to have high [18F]flortaucipir uptake in
PRNP F198S GSS patients belong to the salience net-
work, as well as to the reward system [27]. Reduction in
the function of these networks has been associated with
numerous neuropsychiatric disorders, drug dependence,
and psychosis. Taken together, our findings and those re-
ported in the literature suggest that in GSS patients car-
rying the PRNP F198S allele the behavioral, psychiatric,
and neurological symptoms, as well the dementia that
develops in the late stage, result from the interaction of
misfolded PrP amyloid and tau. The spreading of tau
throughout the entire cerebral cortex and subcortical
nuclei contributes to the progression and severity of the
psychiatric, neurologic, and cognitive dysfunctions [7,
11, 12, 14].
The neuropathologic results observed in Patient B
support the concept that [18F]flortaucipir uptake likely
reflects the anatomical localization of misfolded tau and
NFT that are distributed in the cerebral gray structures.
In fact, there is a definite topographic correspondence
between [18F]flortaucipir uptake and the extent of fluor-
escent NFT in Thioflavin S preparations of cingulate
gyrus, caudate nucleus, putamen, and insular cortex. Im-
munohistochemical preparations of adjacent serially cut
sections of these anatomical regions also revealed a
strong immunoreactivity to monoclonal antibodies AT8
and PHF-1 in the cingulate gyrus, caudate nucleus, puta-
men, and insular cortex. It is also important to note that
no Aβ immunoreactivity was present in any CNS area
affected by PrP or tau pathology.
A finding that needs to be emphasized and that is rele-
vant to the mechanisms of tau spread and to the correla-
tions between [18F]flortaucipir PET images with those
obtained by neuropathologic studies is that many CNS
gray matter regions demonstrated notable tau immuno-
positivity, but not an increased signal on PET images.
This discrepancy may be due to differences in tau spe-
cies in these regions, as [18F]flortaucipir is known to
recognize the NFT, similarly to what Thioflavin S recog-
nizes in histological preparations. Whether [18F]flortaucipir
Fig. 6 PrP and Tau in the Frontal Lobe of the Moderately to Severely Impaired GSS Patient B. PrP amyloid plaques and neurofibrillary tangles
(NFTs) were observed using Thioflavin S in the frontal lobe (a). Significant immunolabeling of PrP amyloid (b; 3F4) and tau (c; AT8; d; PHF-1) was
also observed
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Fig. 7 (See legend on next page.)
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may detect states of tau aggregation that precede NFT for-
mation needs further investigation. Thus, tau immunola-
beled tissue preparations and those stained with Thioflavin
S reveal presence of tau in different states of aggregation.
AT8 or PHF-1 reveal the hyperphosphorylated tau burden,
which is known to be more widespread than that repre-
sented by the fluorescent profiles detected in Thioflavin S
preparations. The process of tau becoming hyperpho-
sphorylated is not completely understood; however, this
process is known to precede tangle formation. Thus, while
Thioflavin S detects only the NFTs made of aggregated tau
filament cores, by knowing which tau epitopes are recog-
nized by AT8 or PHF-1, we can conclude that the labeling
observed in the specific immunohistochemical preparations
recognizes neurons containing not only NFT but also por-
tions of the tau fuzzy coat. It is also possible that the inher-
ent spatial and sensitivity limitations of PET imaging may
lead to an inability to detect low levels of tau deposition in
vivo. Novel tracers with greater specificity for particular tau
filaments are needed [15].
Another region lacking good correspondence between
PET imaging and immunohistochemistry is the thal-
amus, where [18F]flortaucipir uptake is relatively strong
in both patients, but is weak in the immunohistochemi-
cal preparation for tau in GSS Patient B. It should be
noted that the thalamus and cerebellum are strongly la-
beled by immunohistochemistry for PrP; however, no
tau immunopositivity is seen in the cerebellum and only
a weak immunopositivity is detected in the thalamus.
The [18F]flortaucipir PET signal in the thalamus may
represent “off-target” binding similarly to what has been
reported in other studies with [18F]flortaucipir tracer
showing binding to neuromelanin-containing cells and
other targets [22–24]. In view of published studies that
showed high iron binding in GSS patients [11] and
non-specific binding of [18F]flortaucipir to iron [3], we
studied neuropathologically Patient B using a method to
detect iron deposits, and showed that iron deposits
occur mostly in the globus pallidus and the substantia
nigra, but not in the thalamus. Therefore, additional
(See figure on previous page.)
Fig. 7 Comparison of AT8 and PHF-1 Staining to [18F]Flortaucipir in the Moderately to Severely Impaired GSS Patient B. Good correspondence
between the [18F]flortaucipir SUVR (3rd column) and both the AT8 (1st column) and PHF-1 (2nd column) immunolabeling of tau and
neurofibrillary tangles, respectively, was observed across the basal ganglia and cingulate gyrus (a-c), as well as the frontal (a-d) and insular
cortices (b,c,d). However, while the AT8 immunolabeling was more widespread throughout the cortical and subcortical regions, the PHF-1
immunolabeling was more restricted to areas that corresponded to increased [18F]flortaucipir signal, with the exception of the thalamus
Fig. 8 3R and 4R Tau Deposition in the Frontal Lobe of the Moderately to Severely Impaired GSS Patient B. Both 3R (a-b) and 4R (c-d) tau were
observed in GSS Patient B, although the 4R tau appeared to be more prevalent
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studies will be needed to clarify the significance of the
uptake of [18F]flortaucipir in the thalamus.
Overall, the present study shows for the first time that
[18F]flortaucipir detects in vivo the severe neurofibrillary
pathology that is a significant neuropathologic pheno-
type in GSS patients carrying the PRNP F198S mutation,
which potentially has a profound impact on the patho-
genesis of psychiatric and neurological symptoms of the
disease [11, 12, 14]. Based on evidence obtained in two
unpublished presymptomatic mutation carriers, PrP
amyloid deposits are detected prior to the occurrence of
tau pathology and NFT formation; however, additional
in vivo evidence is needed to confirm the PrP-tau rela-
tionship and its temporal evolution [11].
In conclusion, it is shown that deposits of tau are de-
tected in vivo by [18F]flortaucipir PET in patients who
carry the PRNP F198S mutation and that tau accumu-
lates with a pattern that is strikingly different from that
seen in AD. The patterns of tau anatomical spread seen
in GSS PRNP F198S and AD may reflect the mecha-
nisms of PrP and Aβ distribution. The results of this
study support the view that tau pathology, and not just
PrP, contributes significantly to both the psychiatric and
the motor symptoms that characterize the phenotype of
GSS PRNP F198S and that the different clinical pheno-
types of GSS PRNP F198S and AD correlate with the
specific pattern of tau anatomical distribution seen in
each disease.
Future studies, comparing in vivo longitudinal PET
imaging with the post-mortem PrP and tau immunola-
beled preparations may allow a precise assessment of the
spread of the abnormally conformed proteins over time
during the evolution of the PRNP F198S GSS disease
process.
Additional files
Additional file 1: Figure S1. PrP and Tau in the Thalamus of the
Moderately to Severely Impaired GSS Patient B. PrP amyloid plaques were
also observed in the thalamus of GSS Patient B using Thioflavin S (A).
Significant immunolabeling of PrP amyloid (A; 3F4) was also observed.
Diffuse hyperphosphorylated tau was observed using AT8, although the
burden was considerably less than that seen in the other regions of the
brain (C-D). (TIF 3921 kb)
Additional file 2: Table S1. Regional [18F]Flortaucipir SUVR in PRNP
F198S GSS Patients Relative to Early-Onset Alzheimer’s Disease Patients
and Cognitively Normal Older Adults. (DOCX 24 kb)
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Fig. 9 Iron Deposition in the Moderately to Severely Impaired GSS Patient B. Significant iron accumulation is seen in the globus pallidum, as well
as in the caudate and putamen (a). Iron is also observed in the substantia nigra, while minimal iron binding is observed in the thalamus (b)
Risacher et al. Acta Neuropathologica Communications           (2018) 6:114 Page 15 of 17
prepared rapid gradient-echo; MRS: Magnetic resonance spectroscopy; NPI-
Q: Neuropsychiatric Inventory Questionnaire; PiB: [11C]Pittsburgh Compound
B; PrP: Prion protein; PTSD: Post-traumatic stress disorder; RAVLT: Rey
Auditory Verbal Learning Test; rsfMRI: Resting-state functional MRI;
SPECT: Single photon emission computerized tomography; SPM8: Statistical
Parametric Mapping 8; SUVR: Standardized uptake value ratio; TMT-A: Trail
Making Test A; TMT-B: Trail Making Test B; UDS-3: Uniform Dataset 3;
WAIS: Wechsler Adult Intelligence Scale
Acknowledgements
The authors thank Trina Bird, Christina Brown, Steve Brown, Madeline
Cassidy, Ryan Crosbie, Su Gao, Bradley Glazier, Kala Hall, Lili Kyurkchiyska,
Heather Polson, Dr. Adam Schwarz, and Wendy Territo for their contributions
to this work. We would also like to thank Dr. Kimberly Quaid for her
assistance and support with genetic counseling for the patients described in
this manuscript and others in the Indiana Alzheimer Disease Center (IADC).
Funding
This work was supported in part by the National Institute on Aging (NIA, P30
AG010133, R01 AG19771 and K01 AG049050), the Alzheimer’s Association,
the Indiana University Health-Indiana University School of Medicine Strategic
Research Initiative, and the Indiana Clinical and Translational Sciences Insti-
tute (CTSI) and a collaborative research grant from Eli Lilly. Precursor for the
[18F]flortaucipir tracer was provided by Avid Radiopharmaceuticals, a wholly-
owned subsidiary of Eli Lilly. In addition, this research was supported in part
by Lilly Endowment, Inc., through its support for the Indiana University Perva-
sive Technology Institute and the Indiana METACyt Initiative, and, in part,
upon work supported by the National Science Foundation under Grant No.
CNS-0521433.
Availability of data and materials
Data is restricted due to privacy concerns.
Authors’ contributions
All authors contributed to the manuscript. Drs. Risacher, Ghetti, Unverzagt,
and Saykin authored the majority of the text. Drs. Apostolova, Bateman, and
Farlow conducted the clinical and cognitive evaluations of included
participants. Drs. Ghetti and Bonnin were the primary neuropathologists. Dr.
Risacher did the majority of the PET image processing and analysis. Dr.
Murrell was the primary individual responsible for genotyping of the
individuals. Francine Epperson and Rose Richardson were the primary
technologists involved in the neuropathologic analysis. Ms. Tallman was the
primary coordinator responsible for the neuroimaging studies. All authors
reviewed, edited, and approved the final manuscript submission.
Ethics approval and consent to participate
As mentioned in the manuscript, written informed consent was obtained
from all participants in accordance with the Declaration of Helsinki and the
Belmont Report. All procedures were approved by the Indiana University
School of Medicine Institutional Review Board.
Consent for publication
All authors consent to publication. Further, the living GSS participant
consented to and reviewed the publication prior to the original submission.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Radiology and Imaging Sciences, Indiana University School
of Medicine, 355 West 16th Street, Suite 4100, Indianapolis, IN 46202, USA.
2Indiana Alzheimer Disease Center, Indiana University School of Medicine,
Indianapolis, IN, USA. 3Department of Neurology, Indiana University School of
Medicine, Indianapolis, IN, USA. 4Department of Psychiatry, Indiana University
School of Medicine, Indianapolis, IN, USA. 5Department of Pathology and
Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN,
USA. 6Department of Medical and Molecular Genetics, Indiana University
School of Medicine, Indianapolis, IN, USA.
Received: 26 September 2018 Accepted: 28 September 2018
References
1. Alzualde A, Indakoetxea B, Ferrer I, Moreno F, Barandiaran M, Gorostidi A,
Estanga A, Ruiz I, Calero M, van Leeuwen FW et al (2010) A novel PRNP
Y218N mutation in Gerstmann-Straussler-Scheinker disease with
neurofibrillary degeneration. J Neuropathol Exp Neurol 69:789–800. https://
doi.org/10.1097/NEN.0b013e3181e85737
2. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR,
Elizarov A, Kolb HC (2013) Early clinical PET imaging results with the novel
PHF-tau radioligand [F-18]-T807. J Alzheimer's Dis 34:457–468. https://doi.
org/10.3233/JAD-122059
3. Choi JY, Cho H, Ahn SJ, Lee JH, Ryu YH, Lee MS, Lyoo CH (2018) Off-target
(18)F-AV-1451 binding in the basal ganglia correlates with age-related Iron
accumulation. J Nucl Med 59:117–120. https://doi.org/10.2967/jnumed.117.
195248
4. Deters KD, Risacher SL, Yoder KK, Oblak AL, Unverzagt FW, Murrell JR,
Epperson F, Tallman EF, Quaid KA, Farlow MR et al (2016) [(11)C]PiB PET in
Gerstmann-Straussler-Scheinker disease. Am J Nucl Med Mol Imaging 6:84–
93
5. Dickerson B, Domoto-Reilly K, Daisy S, Brickhouse M, Stepanovic M, Johnson
KA (2014) Imaging tau pathology In Vivo in FTLD: initial experience with
[18F]T807 PET. Alzheimer’s Dement 10:P131
6. Dlouhy SR, Hsiao K, Farlow MR, Foroud T, Conneally PM, Johnson P, Prusiner
SB, Hodes ME, Ghetti B (1992) Linkage of the Indiana kindred of Gerstmann-
Straussler-Scheinker disease to the prion protein gene. Nat Genet 1:64–67.
https://doi.org/10.1038/ng0492-64
7. Farlow MR, Yee RD, Dlouhy SR, Conneally PM, Azzarelli B, Ghetti B (1989)
Gerstmann-Sträussler-Scheinker disease. I. Extending the clinical spectrum.
Neurology 39:1446–1452
8. Fitzpatrick AWP, Falcon B, He S, Murzin AG, Murshudov G, Garringer HJ,
Crowther RA, Ghetti B, Goedert M, Scheres SHW (2017) Cryo-EM structures
of tau filaments from Alzheimer's disease. Nature 547:185–190. https://doi.
org/10.1038/nature23002
9. Gerstmann J, Straussler E, Scheinker I (1936) Uber eine eigenartige hereditar-
familiare Erkrankung des Zentralnervensystems. Zugleich ein Beitrag zur Frage
des vorzeitigen lokalen Alters. Z Neur Psychiat 154:736–762
10. Ghetti B, Bugiani O, Tagliavini F, Piccardo P (2011) Gerstmann–Sträussler–
Scheinker Disease. In: Dickson DW, Weller RO (eds) Neurodegeneration: the
molecular pathology of dementia and movement disorders 2 edn. Wiley-
Blackwell, City, pp 364–377
11. Ghetti B, Dlouhy SR, Giaccone G, Bugiani O, Frangione B, Farlow MR,
Tagliavini F (1995) Gerstmann-Straussler-Scheinker disease and the Indiana
kindred. Brain Pathol 5:61–75
12. Ghetti B, Tagliavini F, Giaccone G, Bugiani O, Frangione B, Farlow MR,
Dlouhy SR (1994) Familial Gerstmann-Straussler-Scheinker disease with
neurofibrillary tangles. Mol Neurobiol 8:41–48. https://doi.org/10.1007/
BF02778006
13. Ghetti B, Tagliavini F, Hsiao K, Dlouhy SR, Yee RD, Giaccone G, Conneally
PM, Hodes ME, Bugiani O, Prusiner SB et al (1992) Indiana variant of
Gerstmann-Straussler-Scheinker disease. In: Prusiner SB, Collinge J, Powell J,
Anderton B (eds) Prion diseases of humans and animals. Ellis Horwood Ltd.,
Hemel Hempstead, Hertfordshire, UK, pp 154–167
14. Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G, Verga L, Farlow
MR, Conneally PM, Dlouhy SR, Azzarelli B et al (1989) Gerstmann-Straussler-
Scheinker disease. II. Neurofibrillary tangles and plaques with PrP-amyloid
coexist in an affected family. Neurology 39:1453–1461
15. Goedert M, Yamaguchi Y, Mishra SK, Higuchi M, Sahara N (2018) Tau
filaments and the development of positron emission tomography tracers.
Front Neurol 9:70. https://doi.org/10.3389/fneur.2018.00070
16. Hsiao K, Dlouhy SR, Farlow MR, Cass C, Da Costa M, Conneally PM, Hodes
ME, Ghetti B, Prusiner SB (1992) Mutant prion proteins in Gerstmann-
Sträussler-Scheinker disease with neurofibrillary tangles. Nat Genet 1:68–71.
https://doi.org/10.1038/ng0492-68
17. Jansen C, Parchi P, Capellari S, Vermeij AJ, Corrado P, Baas F, Strammiello R,
van Gool WA, van Swieten JC, Rozemuller AJ (2010) Prion protein
amyloidosis with divergent phenotype associated with two novel nonsense
Risacher et al. Acta Neuropathologica Communications           (2018) 6:114 Page 16 of 17
mutations in PRNP. Acta Neuropathol 119:189–197. https://doi.org/10.1007/
s00401-009-0609-x
18. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D,
Mormino E, Chhatwal J, Amariglio R, Papp K et al (2016) Tau positron
emission tomographic imaging in aging and early Alzheimer disease.
Ann Neurol 79:110–119. https://doi.org/10.1002/ana.24546
19. Kepe V, Ghetti B, Farlow MR, Bresjanac M, Miller K, Huang SC, Wong KP,
Murrell JR, Piccardo P, Epperson F et al (2010) PET of brain prion
protein amyloid in Gerstmann-Straussler-Scheinker disease. Brain
pathology 20:419–430. https://doi.org/10.1111/j.1750-3639.2009.00306.x
20. Kumar N, Boeve BF, Boot BP, Orr CF, Duffy J, Woodruff BK, Nair AK,
Ellison J, Kuntz K, Kantarci K et al (2011) Clinical characterization of a
kindred with a novel 12-octapeptide repeat insertion in the prion
protein gene. Arch Neurol 68:1165–1170. https://doi.org/10.1001/
archneurol.2011.187
21. Laplanche JL, Hachimi KH, Durieux I, Thuillet P, Defebvre L, Delasnerie-
Laupretre N, Peoc'h K, Foncin JF, Destee A (1999) Prominent psychiatric
features and early onset in an inherited prion disease with a new insertional
mutation in the prion protein gene. Brain 122(Pt 12):2375–2386
22. Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA, Parisi JE, Kantarci K,
Boeve BF, Pandey MK, Bruinsma T et al (2016) An autoradiographic
evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 4:
58. https://doi.org/10.1186/s40478-016-0315-6
23. Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA,
Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML et al
(2015) Validating novel tau positron emission tomography tracer [F-18]-
AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787–800.
https://doi.org/10.1002/ana.24517
24. Marquie M, Verwer EE, Meltzer AC, Kim SJW, Aguero C, Gonzalez J, Makaretz
SJ, Siao Tick Chong M, Ramanan P, Amaral AC et al (2017) Lessons learned
about [F-18]-AV-1451 off-target binding from an autopsy-confirmed
Parkinson's case. Acta Neuropathol Commun 5:75. https://doi.org/10.1186/
s40478-017-0482-0
25. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas
CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R et al (2011) The
diagnosis of dementia due to Alzheimer's disease: recommendations
from the National Institute on Aging-Alzheimer's Association
workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers
Dement 7:263–269. https://doi.org/10.1016/j.jalz.2011.03.005
26. Mead S, Gandhi S, Beck J, Caine D, Gallujipali D, Carswell C, Hyare H,
Joiner S, Ayling H, Lashley T et al (2013) A novel prion disease
associated with diarrhea and autonomic neuropathy. N Engl J Med 369:
1904–1914. https://doi.org/10.1056/NEJMoa1214747
27. Menon V (2015) Salience network. In: Toga AW (ed) Brain mapping: an
encyclopedic reference. Elsevier, City, pp 597–611
28. Ossenkoppele R, Schonhaut DR, Baker SL, O'Neil JP, Janabi M, Ghosh PM,
Santos M, Miller ZA, Bettcher BM, Gorno-Tempini ML et al (2015) Tau,
amyloid, and hypometabolism in a patient with posterior cortical atrophy.
Ann Neurol 77:338–342. https://doi.org/10.1002/ana.24321
29. Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL,
O'Neil JP, Janabi M, Lazaris A, Cantwell A et al (2016) Tau PET patterns
mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain
139:1551–1567. https://doi.org/10.1093/brain/aww027
30. Paucar M, Xiang F, Moore R, Walker R, Winnberg E, Svenningsson P (2013)
Genotype-phenotype analysis in inherited prion disease with eight
octapeptide repeat insertional mutation. Prion 7:501–510
31. Piccardo P, Dlouhy S, Lievens P, Young K, Bird T, Nochlin D, Dickson D,
Vinters H, Zimmerman T, Mackenzie I et al (1998) Phenotypic variability
of Gerstmann-Straussler-Scheinker disease is associated with prion
protein heterogeneity. J Neuropathol Exp Neurol 57:979–988
32. Suhara T, Shimada H, Shinotoh H, Hirano S, Eguchi Y, Takahata K,
Kimura Y, Yamada M, Ito H, Higuchi M (2014) In vivo tau PET imaging
using [11C]PBB3 in Alzheimer's disease and non-Alzheimer's disease
tauopathies. J Nucl Med 55:1824
33. Tagliavini F, Giaccone G, Prelli F, Verga L, Porro M, Trojanowski JQ, Farlow
MR, Frangione B, Ghetti B, Bugiani O (1993) A68 is a component of paired
helical filaments of Gerstmann-Straussler-Scheinker disease, Indiana kindred.
Brain Res 616:325–329
34. Trzepacz PT, Hochstetler H, Wang S, Walker B, Saykin AJ, Alzheimer's Disease
Neuroimaging I (2015) Relationship between the Montreal cognitive
assessment and mini-mental state examination for assessment of mild
cognitive impairment in older adults. BMC Geriatr 15:107. https://doi.org/10.
1186/s12877-015-0103-3
35. Unverzagt FW, Farlow MR, Norton J, Dlouhy SR, Young K, Ghetti B
(1997) Neuropsychological function in patients with Gerstmann-
Sträussler-Scheinker disease from the Indiana kindred (F198S). J Int
Neuropsychol Soc 3:169–178
36. Vitali P, Maccagnano E, Caverzasi E, Henry RG, Haman A, Torres-Chae C,
Johnson DY, Miller BL, Geschwind MD (2011) Diffusion-weighted MRI
hyperintensity patterns differentiate CJD from other rapid dementias.
Neurology 76:1711–1719. https://doi.org/10.1212/WNL.0b013e31821a4439
37. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C,
Liang Q, Liu C, Mocharla VP et al (2013) [(18)F]T807, a novel tau positron
emission tomography imaging agent for Alzheimer's disease. Alzheimers
Dement 9:666–676. https://doi.org/10.1016/j.jalz.2012.11.008
Risacher et al. Acta Neuropathologica Communications           (2018) 6:114 Page 17 of 17
